Pertuzumab: A novel humanized mAb for the treatment of HER2 positive breast cancer.

1. Pertuzumab: A novel humanized mAb
for the treatment of HER2 positive
breast cancer.
Prepared by :
Md. Mominul Islam
ID # 162 1405 673
North South University_Mpharm_Summer-17

3. Breast Cancer Facts…
2nd position in case of
cancer deaths.
In every 13 minutes 1
woman will die.

4. Breast Cancer Prevalence in
Bangladesh
Approximately 1.5 lac women
die each year due to cancer
in Bangladesh.
WHO ranked
Bangladesh 2nd
position in mortality
rate of women due
to breast cancer.

5. Types of Breast Cancer

6. HER-2 Positive Breast Cancer

7. HER-2 Positive Breast Cancer
• HER-2 is a protein found on
the surface of normal breast
cells.
• Over expression of these
cells cause HER-2 positive
breast cancer
* HER-2 : Human Epidermal Growth factor receptor-2

8. HER2-HER3 Dimerization
Most potent dimer in the development of HER2 positive breast
cancer

9. Treatment

10. Targeted Therapy-Pertuzumab
The HER2-HER3 dimerization inhibitor.
Pertuzumab gives complementary functions in
combination with Trastuzumab and Docetaxel to
block HER2-HER3 dimerization.

11. Pertuzumab
A novel humanized monoclonal Antibody
It’s development for medical use began in1990
First Marketed as Perjeta by Genetech.

12. Pertuzumab Recommendations

13. Mode of Action

14. Unique Features…
Selectively blocks the HER2 receptor
Only Pertuzumab Inhibits HER2-HER3
dimerization other than Trastuzumab &
Docetaxel.
In combination with Trastuzumab and
Docetaxel, produces better results in
HER2 positive breast cancer
No safety & efficacy limitations observed
with age

15. Why better than existing Drugs?
Conventional treatment of HER2 positive breast cancer
Docetaxel and Trastuzumab blocks HER2-HER2 dimer only,
But
Unable to block the most potent HER2-HER3 dimer.
Where
Pertuzumab can.

16. Pertuzumab VS Trastuzumab with Docetaxel
for neoadjuvant therapy in HER2(+) BC.
Dose:
 Pertuzumab initially 840 mg,
followed by 420 mg for 3 weeks.
 Trastuzumab initially of 8
mg/kg, followed by 6 mg/kg for
3 weeks
 Docetaxel 75-100mg/m2 every
3 weeks
** no. of patients 214
Pertuzumab+Trastuzumab
+Docetaxel
Trsatuzumab+Docetaxel
46%
29%
Complete pathological response in %

17. Pertuzumab VS Trastuzumab with Docetaxel
in metastatic breast cancer.
Dose:
 Pertuzumab initially 840 mg,
followed by 420 mg for 3 weeks.
 Trastuzumab initially of 8 mg/kg,
followed by 6 mg/kg for 3 weeks
 Docetaxel 75-100mg/m2 every 3
weeks
* *No of patients 808

18. Pertuzumab+Gemcitabine Vs Placebo+Gemcitabine in
ovarian cancer treatment
Dose:
 Pertuzumab initially 840 mg,
followed by 420 mg for 3
weeks.
 Gemcitabine 800 mg/m2
for 3 weeks

19. Prescribing Information
Indication:
Metastatic HER2 Breast Cancer, Neoadjuvant Treatment of Breast
Cancer
Dosage and Adminstration:
For intravenous infusion only.
Do not administer as an intravenous push or bolus.
The initial dose is 840 mg as a 60-minute IV infusion, followed every
3 weeks thereafter by 420 mg as a 30 to 60 minute IV infusion.
Precaution:
Special precautions should be taken in patients with cardiac
dysfunctions.

20. Prescribing Information
Pregnancy Category D:
Pertuzumab is contraindicated in pregnancy.
During Lactation:
Breast feeding should be avoided during treatment with Pertuzumab.
Pediatric Use:
Safety and effectiveness of Pertuzumab have not been established in pediatric
patients.
Drug interactions:
Patients who receive anthracycline after receiving Pertuzumab maybe at
increased risk of cardiac dysfunction.
Contraindications:
Pertuzumab is contraindicated in patients with known hypersensitivity to
Pertuzumab or to any of its excipients.